Rucha Patil: Health Technology Assessment and the Future of Haemophilia Care in India at NHU 2026
Rucha Patil, Scientist at Department of Haemostasis and Thrombosis, ICMR- National Institute of Immunohaematology, shared on LinkedIn:
“One of the most engaging sessions at the 15th National Haemostasis Update 2026 (1–2 August, Bengaluru) organised by Indian Association for Haemophilia and Allied Disorders was on HTA Assessment: Indian Scenario (DHR-ICMR session)
The session featured:
- Dr. Kavita Rajshekar – an excellent overview of HTA in India, its framework, implementation, and impact.
- My presentation – the multicentre pooled emicizumab data from 773 Indian patients.
- Dr. Sitanshu Sekhar Kar – a comprehensive explanation of the HTA model, key assumptions, budget impact, and decision-making process.
It was a privilege to share the stage with distinguished experts and present the Indian pooled analysis of 773 patients with hemophilia A receiving emicizumab prophylaxis, which formed an important part of the Health Technology Assessment undertaken by the JIPMER HTA team under HTAIn, Department of Health Research (DHR), Government of India.
The thought-provoking discussion and numerous questions from the audience highlighted the growing importance of Health Technology Assessment (HTA) in translating robust clinical evidence into informed healthcare policy and improving patient access.
Grateful to the organizers for including this important session in an outstanding scientific program.”

Stay updated with Hemostasis Today.
-
Nov 14, 2026, 10:00Benjamin Tur: Putting Iron Deficiency Anemia on the Global Agenda at the Paris Peace Forum’s Child Summit
-
Nov 14, 2026, 09:48Jack Shuang Hou: FDA Approves Bayer’s Sunharbo – First Factor XIa Inhibitor for Secondary Stroke Prevention
-
Nov 14, 2026, 09:42Samwel Mikaye: What Every Patient Should Know About DVT Symptoms and Treatment
-
Nov 14, 2026, 09:37Chronic Preoperative Corticosteroid Use and Postoperative Venous Thromboembolism Risk – Thrombosis and Haemostasis Journal
-
Nov 14, 2026, 09:30Ney Carter Borges: Vulnerable Plaque – Imaging and Clinical Significance
-
Nov 14, 2026, 09:25Carmelo Raffo: How Much Antithrombotic Therapy is Truly Necessary after LAAC?
-
Nov 14, 2026, 09:19Mary Cushman: Excellent to Have Jordan Shavit Visit Us for a Virtual Lab Meeting Today
-
Nov 14, 2026, 09:15Chancellor Donald: Heading to ASH 2026 in New Orleans? Let’s Connect on Faculty Opportunities at Tulane
-
Nov 14, 2026, 09:11Sajja Venkatesh: FDA Approved Asundexian, the First Factor XIa Inhibitor